Enanta Pharmaceuticals (ENTA) EBITDA Margin (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly EBITDA Margin came in at 69.07% in Q1 2026, up 9525.0% YoY from 0.72% in Q1 2025, and down 14.26% on a QoQ basis from 60.45% in Q4 2025.
Enanta Pharmaceuticals (ENTA) EBITDA Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of EBITDA Margin data on file, last reported at 69.07% in Q1 2026.
- Quarterly EBITDA Margin rose 9525.0% year-over-year to 69.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 87.24% (up 7116.0% YoY) and the FY2025 annual result came in at 130.65%, up 4927.0% from the prior year.
- EBITDA Margin retreated to 69.07% in Q1 2026, from 60.45% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 60.45% in Q4 2025 to a low of 221.7% in Q1 2023.
- A 5-year average of 151.2% and a median of 163.9% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2023 — EBITDA Margin tumbled 6652 bps — and 2026, when it surged 9525 bps.
- Tracing ENTA's EBITDA Margin over 5 years: stood at 127.25% in 2022, then slumped by 52 bps to 193.78% in 2023, then rose by 28 bps to 138.82% in 2024, then jumped by 56 bps to 60.45% in 2025, then slipped by 14 bps to 69.07% in 2026.
- The last three EBITDA Margin figures came in at 69.07% (Q1 2026), 60.45% (Q4 2025), and 121.56% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -120.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -120.04% |
| Mar 31, 2026 | -69.07% |
| Dec 31, 2025 | -60.45% |
| Sep 30, 2025 | -121.56% |
| Jun 30, 2025 | -103.16% |
| Mar 31, 2025 | -164.32% |
| Dec 31, 2024 | -138.82% |
| Sep 30, 2024 | -204.38% |
| Jun 30, 2024 | -134.58% |
| Mar 31, 2024 | -192.13% |
| Dec 31, 2023 | -193.78% |
| Sep 30, 2023 | -163.90% |
| Jun 30, 2023 | -194.33% |
| Mar 31, 2023 | -221.70% |
| Dec 31, 2022 | -127.25% |
| Sep 30, 2022 | -133.13% |
| Jun 30, 2022 | -167.05% |
| Mar 31, 2022 | -180.85% |
| Dec 31, 2021 | -109.99% |
| Sep 30, 2021 | -143.06% |